Stock MIRM MIRUM PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Mirum Pharmaceuticals, Inc.

Equities

MIRM

US6047491013

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-05 pm EDT 		5-day change 1st Jan Change
26.3 USD +1.98% Intraday chart for Mirum Pharmaceuticals, Inc. +8.63% -10.91%
May. 31 Mirum Pharmaceuticals Gets Positive Opinion From EU Committee on Marketing Authorization for Livmarli to Treat PFIC MT
May. 31 Mirum Pharmaceuticals Announces Positive Chmp Opinion for Livmarli® (Maralixibat) Oral Solution for the Treatment of Pfic in Patients Three Months of Age and Older CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Mirum Pharmaceuticals Gets Positive Opinion From EU Committee on Marketing Authorization for Livmarli to Treat PFIC
MT
Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for the Treatment of PFIC in Patients Three Months of Age and Older
BU
Mirum Pharmaceuticals Announces Positive Chmp Opinion for Livmarli® (Maralixibat) Oral Solution for the Treatment of Pfic in Patients Three Months of Age and Older
CI
Long-Term Data from Mirum's LIVMARLI Studies in ALGS and PFIC to be presented at EASL Congress
AQ
Long-Term Data from Mirum’s LIVMARLI Studies in ALGS and PFIC to be Presented at EASL Congress
BU
Mirum Pharmaceuticals LIVMARLI Data Showcased at ESPGHAN Annual Meeting
AQ
Mirum Pharmaceuticals’ LIVMARLI Data Showcased at ESPGHAN Annual Meeting
BU
Mirum Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(4)
AQ
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Morgan Stanley Adjusts Price Target on Mirum Pharmaceuticals to $53 From $57, Keeps Overweight Rating
MT
Mirum Pharmaceuticals, Inc. Reiterates Revenue Guidance for the Year 2024
CI
Transcript : Mirum Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 08, 2024
Mirum Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Earnings Flash (MIRM) MIRUM PHARMACEUTICALS Posts Q1 Revenue $69.2M, vs. Street Est of $70.2M
MT
Mirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
BU
Mirum Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference
BU
Mirum Announces Publication of Phase 3 MARCH Data in The Lancet Demonstrating Benefits of LIVMARLI (maralixibat) in patients with PFIC
BU
Mirum Pharmaceuticals, Inc Publication of Phase 3 MARCH Data in The Lancet Demonstrating Benefits of LIVMARLI (maralixibat) in patients with PFIC
CI
Mirum Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
BU
Stifel Initiates Mirum Pharmaceuticals With Buy Rating, $48 Price Target
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MIRM Stock
  4. News Mirum Pharmaceuticals, Inc.